Category: Corporate NewsBy adminNovember 10, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to EGX on BOD minutesNextNext post:Disclosure to EGX regarding the contact information for Investor Relations departmentRelated PostsEarning Release One Pager 3Q24November 14, 2024Rameda Completes Largest Acquisition to DateSeptember 30, 2024Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024Earning Release One Pager 2Q24August 13, 2024Rameda Announces Price Increase Approvals for All Its Top ProductsAugust 7, 2024Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
Rameda Announces the Establishment of Glow: A Strategic Expansion into the Thriving Freely Priced Cosmeceutical MarketSeptember 9, 2024
Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceMay 28, 2024
